Fig. 4From: Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironmentCB-1158 requires an intact immune system for efficacy. a CellTiterGlo assays (72 h) were performed on the indicated cell lines with a dose-titration of CB-1158. b B6.CB17-Prkdc (SCID)/SzJ mice were implanted with LLC cells and CB-1158 was dosed 100 mg/kg twice daily. c-e Tumor growth inhibition by CB-1158 in the B16 (c), CT26 (d), and LLC (e) models is mediated by CD8+ and NK cells. Tumor-bearing mice were treated with depleting antibodies and dosed twice-daily with vehicle or 100 mg/kg CB-1158. Tumors from LLC studies were analyzed on study day 13 (CD8+ cell depletion) or study day 14 (NK cell depletion). (**** P < 0.0001; *** P < 0.001; ** P < 0.01)Back to article page